COVID-19 vaccine lowers risk of severe exacerbation in asthmatic patients by up to 72 percent

Aug 28, 2025

COVID-19 vaccine lowers risk of severe exacerbation in asthmatic patients by up to 72 percent
data photo source=Pixabay



A joint research team led by Kim Sang-hyuk, a professor of respiratory allergies at Korea University Guro Hospital (Lee Hyun, a professor of respiratory allergies at Hanyang University Hospital, Kim Jong-seung, an otolaryngology professor at Chonbuk National University Hospital, and Jang Jong-gul, a professor of respiratory allergies at Yeungnam University Hospital) announced that COVID-19 vaccination significantly reduces the risk of severe exacerbation in asthma patients.

Professor Kim's research team conducted the study through a large national-based cohort study using the NHIS database, and analyzed 3,380 asthma patients by classifying them into four groups: ▲ unvaccinated and uninfected (845) ▲ unvaccinated and infected (845) ▲ unvaccinated and uninfected (845) ▲ vaccinated and infected (845) according to COVID-19 infection and vaccination status.

As a result, the research team proved through large-scale data that the COVID-19 vaccine can reduce the risk of severe exacerbation by up to 72% in asthma patients beyond simple infection prevention. The risk of severe exacerbation in the inoculated and uninfected groups decreased by 72%, and the unvaccinated and uninfected groups also decreased by 56%. In addition, a 37% reduction was confirmed in the inoculated and infected groups, proving that vaccination provides clear protection regardless of infection. On the other hand, the unvaccinated and infected group showed the highest risk of exacerbation.




In addition, the research team confirmed that even if they experienced COVID-19 infection, vaccinated patients had a significantly reduced risk of severe exacerbation, and confirmed that the vaccine could contribute to long-term management of asthma patients after infection. In particular, changes in the immune system and decreased physical function in COVID-19 recovery patients can increase the risk of asthma exacerbation in the future, and it has been found that vaccination acts as a shield to block this vicious cycle.

Professor Kim Sang-hyuk of the Department of Respiratory Medicine at Korea University Guro Hospital said "I think it is a very important finding clinically that the COVID-19 vaccine has been confirmed to be effective in preventing severe exacerbation of asthma patients."The results of this study show that vaccination should be actively considered in the treatment and management of asthma patients. We will continue to conduct research to improve the health of patients in the future."

Meanwhile, the study was published in Allergy, a prestigious international academic journal in the field of allergy and respiratory diseases, under the title "The Role of COVID-19 Vaccination on COVID-19 Vacancy on Future Sever Exhibition: A Nationwide Population-Based Cohort Study."






COVID-19 vaccine lowers risk of severe exacerbation in asthmatic patients by up to 72 percent
(from left) Kim Sang-hyuk, a professor of respiratory medicine at Korea University Guro Hospital, Lee Hyun, a professor of respiratory allergies at Hanyang University Hospital, Kim Jong-seung, an otolaryngologist at Chonbuk National University Hospital, Jang Jong-gul, a professor of respiratory allergies at Yeungnam University Hospital


This article was translated by Naver AI translator.